Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Liu Hui, MD, Li Xuan, MD, Ren Lin, MD, Lan Deng, MD PhD, Fen Huang, MD, Zhiping Fan, MD, Danian Nie, MD, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, MD, Jieyu Ye, MD PhD, Hua Jin, Dongjun Lin, MD, Liping MA, MD, Jing Sun, MD, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 3303.

https://doi.org/10.1182/blood-2019-126901

Published: 2019

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Journal Articles

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Weijun Zhou, MD PhD, Jilong Yang, MD, Chunyan Yue, MD, Anqin Wu, Meifang Li, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2018-99-118928

Published: 2018

Journal Articles

Efficacy and Safety of Ruxolitinib in Treatment of Steroid Refractory/Refractory Acute Graft-Versus-Host Disease: A Prospective Multicenter Research

Zhiping Fan, MD, Lan Deng, MD PhD, Xudong Li, Qing Zhang, MD, Li Xuan, Fen Huang, Ren Lin, Hua Jin, Na Xu, PhD, Pengcheng Shi, Zhixiang Wang, PhD, Jieyu Ye, Ling Jiang, Jing Sun, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5724.

https://doi.org/10.1182/blood-2018-99-117430

Published: 2018

Journal Articles

Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT

Li Xuan, Yu Wang, Jia Chen, Erlie Jiang, Li Gao, Bingyi Wu, MD, Lan Deng, MD PhD, Xinquan Liang, Fen Huang, Zhiping Fan, Xiaowen Tang, Jing Sun, Xi Zhang, Ming-Zhe Han, De-Pei Wu, Xiao Jun Huang, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2018-99-114103

Published: 2018

NARROW

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety of Ruxolitinib in Treatment of Steroid Refractory/Refractory Acute Graft-Versus-Host Disease: A Prospective Multicenter Research

Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT

Email alerts

ASH Publications

American Society of Hematology

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety of Ruxolitinib in Treatment of Steroid Refractory/Refractory Acute Graft-Versus-Host Disease: A Prospective Multicenter Research

Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only